Interpreting the clinical utility of a pharmacogenomic marker based on observational association studies

Pharmacogenomics Journal

Volumn 14, Issue 1, 2014, Pages 1-5

  Sorich, M J ^a   Coory, M ^b  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

Author keywords

association study; clinical utility; observational study; personalized medicine; pharmacogenetics

Indexed keywords

B RAF KINASE; K RAS PROTEIN;

EVIDENCE BASED MEDICINE; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MARKER GENE; OBSERVATIONAL STUDY; PHARMACOGENOMICS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

BIOLOGICAL MARKERS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EVIDENCE-BASED MEDICINE; HUMANS; OBSERVATIONAL STUDY AS TOPIC; PHARMACOGENETICS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RESEARCH DESIGN;

EID: 84893697121     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2013.35     Document Type: Review

References (35)

1. Hingorani AD, DAvd Windt, Riley RD, Abrams K, Moons KGM, Steyerberg EW et al. Prognosis research strategy (PROGRESS) 4: stratified medicine research. BMJ 2013; 346: e5793.
2. Sorich MJ, McKinnon RA. Personalized medicine: potential, barriers and contemporary issues. Curr Drug Metab 2012; 13: 1000-1006.
3. Lesko LJ, Zineh I, Huang SM. What is clinical utility and why should we care? Clin Pharmacol Ther 2010; 88: 729-733.
4. Teutsch SM, Bradley LA, Palomaki GE, Haddow JE, Piper M, Calonge N et al. The evaluation of genomic applications in practice and prevention (EGAPP) initiative: Methods of the EGAPP working group. Genet Med 2009; 11: 3-14.
5. McKinnon RA, Ward MB, Sorich MJ. A critical analysis of barriers to the clinical implementation of pharmacogenomics. Ther Clin Risk Manag 2007; 3: 751-759.
6. Meckley LM, Neumann PJ. Personalized medicine: factors influencing reimbursement. Health Policy 2010; 94: 91-100.
7. Paci D, Ibarreta D. Economic and cost-effectiveness considerations for pharmacogenetics tests: An integral part of translational research and innovation uptake in personalized medicine. Curr Pharmacogenomics Person Med 2009; 7: 284-296.
8. Oldenhuis CNAM, Oosting SF, Gietema JA, de Vries EGE. Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer 2008; 44: 946-953.
9. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
10. Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol 2009; 27: 4027-4034.
11. Patterson SD, Cohen N, Karnoub M, Truter SL, Emison E, Khambata-Ford S et al. Prospective-retrospective biomarker analysis for regulatory consideration: white paper from the industry pharmacogenomics working group. Pharmacogenomics 2011; 12: 939-951.
12. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009; 101: 1446-1452.
13. Karapetis CS, Khambata-Ford S, Jonker DJ, OCallaghan CJ, Tu D, Tebbutt NC et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765.
14. Bokemeyer C, Cutsem EV, Rougier P, Ciardiello F, Heeger S, Schlichting M et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 2012; 48: 1466-1475.
15. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
16. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24: 3726-3734.
17. Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA 2011; 306: 2704-2714.
18. Sorich MJ, Vitry A, Ward MB, Horowitz JD, McKinnon RA. Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI trial data. J Thromb Haemost 2010; 8: 1678-1684.
19. Sorich MJ, Polasek TM, Wiese MD. Systematic review and meta-analysis of the association between cytochrome P450 2C19 genotype and bleeding. Thromb Haemost 2012; 108: 199-200.
20. Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: A genetic substudy of the PLATO trial. Lancet 2010; 376: 1320-1328.
21. Sorich MJ, Polasek TM, Wiese MD. Challenges and limitations in interpretation of systematic reviews: making sense of clopidogrel and CYP2C19 pharmacogenetics. Clin Pharmacol Ther 2013; 94: 376-382.
22. Topol EJ, Damani SB. The KIF6 Collapse. J Am Coll Cardiol 2010; 56: 1564-1566.
23. Sorich M, Wiese M, OShea R, Pekarsky B. Review of the cost effectiveness of pharmacogenetic-guided treatment of hypercholesterolaemia. Pharmacoeconomics 2013; 31: 377-391.
24. Iakoubova OA, Robertson M, Tong CH, Rowland CM, Catanese JJ, Blauw GJ et al. KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study. Eur J Cardiovasc Prev Rehabil 2010; 17: 455-461.
25. Assimes TL, Hólm H, Kathiresan S, Reilly MP, Thorleifsson G, Voight BF et al. Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. J Am Coll Cardiol 2010; 56: 1552-1563.
26. Celera Says Case-control Publication on KIF6 Does Not Refute Prior Research on KIF6s Association with Coronary Heart Disease and Statin Benefit [Press release] 2010. www.celera.com/celera/pr-1286482527.
27. Khoury MJ, Berg A, Coates R, Evans J, Teutsch SM, Bradley LA. The evidence dilemma in genomic medicine. Health Aff (Millwood) 2008; 27: 1600-1611.
28. Chen P, Lin JJ, Lu CS, Ong CT, Hsieh PF, Yang CC et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med 2011; 364: 1126-1133.
29. French B, Joo J, Geller NL, Kimmel SE, Rosenberg Y, Anderson JL et al. Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Trials 2010; 11: 108.
30. van Schie RM, Wadelius MI, Kamali F, Daly AK, Manolopoulos VG, de Boer A et al. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics 2009; 10: 1687-1695.
31. Zujewski JA, Kamin L. Trial assessing individualized options for treatment for breast cancer: the TAILORx trial. Future Oncol 2008; 4: 603-610.
32. Cardoso F, Vant Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ. Clinical application of the 70-gene profile: the MINDACT trial. J ClinOncol 2008; 26: 729-735.
33. Sorich MJ, Coory M, Pekarsky BAK. Indirect estimation of the comparative treatment effect in pharmacogenomic subgroups. PLoS One 2013; 8: e72256.
34. Punglia RS, Burstein HJ, Winer EP, Weeks JC. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst 2008; 100: 642-648.
35. Woods B, Veenstra D, Hawkins N. Prioritizing pharmacogenetic research: a value of information analysis of CYP2D6 testing to guide breast cancer treatment. Value Health 2011; 14: 989-1001.